Is there a role for nitric oxide in β-cell dysfunction and damage in IDDM?

Diabetes/Metabolism Reviews

Volumn 13, Issue 4, 1997, Pages 293-307

  Eizirik, Décio L ^a   Pavlovic, Dejan ^a  

^a DIABETES RESEARCH CENTER   (Belgium)

Author keywords

Apoptosis; Cytokines; Diabetes mellitus; Interferon ; Interleukin 1; Nitric oxide

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE;

AUTOIMMUNITY; CELL DAMAGE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; ISLETS OF LANGERHANS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS;

EID: 0031426764     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199712)13:4<293::AID-DMR195>3.0.CO;2-4     Document Type: Review

References (120)

1. Pozzilli P: Prevention of insulin-dependent diabetes: where are we now? Diabetes Metab Rev 12: 127-135, 1996.
2. Eisenbarth GS: Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 314: 1360-1368, 1986.
3. Eizirik DL, Sandier S, and Palmer JP: Repair of pancreatic β-cells: a relevant phenomenon in early IDDM? Diabetes 42: 1383-1391, 1993.
4. Pipeleers D, and Ling Z: Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8: 209-227, 1992.
5. Bach JF: Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. J Autoimmun 8: 439-463, 1995.
6. Eizirik DL: Beta-cell defence and repair mechanisms in human pancreatic islets. Horm Metab Res 28: 302-305, 1996.
7. Rabinovitch A: Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev 1: 215-240, 1993.
8. Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39: 1005-1029, 1996.
9. Moncada S, and Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
10. Gross SS, and Wolin MS: Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 57: 737-769, 1995.
11. Kroncke KD, Fehsel K, and Kolb-Bachofen V: Nitric oxide: cytotoxicity versus cytoprotection - how, why, when, and where? Nitric Oxide: Biol Chem 1: 107-120, 1997.
12. Xie Q, and Nathan C: The high-output nitric oxide pathway: role and regulation. J Leukoc Biol 56: 576-582, 1994.
13. Griffith OW, and Stuehr DJ: Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 57: 707-736, 1995.
14. Eizirik DL, Flodström M, Karlsen AE, and Welsh N: The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta-cells. Diabetologia 39: 875-890, 1996.
15. MacMicking J, Xie QW, and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.
16. Vladutiu AO: Role of nitric oxide in autoimmunity. Clin Immunol Immunopathol 76: 1-11, 1995.
17. Lundberg JO, Hellstrom PM, Lundberg JM, and Alving K: Greatry increased luminal nitric oxide in ulcerative colitis. Lancet 344: 1673-1674, 1994.
18. Cochran FR, Selph J, and Sherman P: Insights into the role of nitric oxide in inflammatory arthritis. Med Res Rev 16: 547-563, 1996.
19. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, and Koprowski H: Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94: 2528-2533, 1997.
20. Corbett JA, and McDaniel ML: Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41: 897-903, 1992.
21. Kolb H, and Kolb-Bachofen V: Type 1 (insulin-dependent) diabetes mellitus and nitric oxide. Dinabetologia 35: 796-797, 1992.
22. Welsh N, Eizirik DL, and Sandier S: Nitric oxide and pancreatic β-cell destruction in insulin dependent diabetes mellitus: don't take NO for an answer. Autoimmunity 18: 285-290, 1994.
23. Sandier S, Eizirik DL, Svensson C, Strandell E, Welsh M, and Welsh N: Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 10: 241-253, 1991.
24. Eizirik DL, Strandell E, Bendtzen K, and Sandier S: Functional characteristics of rat pancreatic islets maintained in culture after exposure to human interleukin-1. Diabetes 37: 916-919, 1988.
25. Eizirik DL, Sandler S, Hallberg A, Bendtzen K, Sener A, and Malaisse WJ: Differential sensitivity to β-cell secretagogues in cultured rat pancreatic islets exposed to human interleukin1β. Endocrinology 125: 752-759, 1989.
26. Southern C, Schulster D, and Green IC: Inhibition of insulin secretion by interleukin-1β and tumour necrosis factor-α via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett 276; 42-44, 1990.
27. Welsh N, Eizirik DL, Bendtzen K, and Sandler S: Inter Ieukin-1β-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 129: 3167-3173, 1991.
28. Eizirik DL: Interleukin-1-induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinol Copenh 119: 321-325, 1988.
29. Eizirik DL, Welsh N, Niemann A, Velloso LA, and Malaisse WJ: Succinic acid monomethyl ester protects rat pancreatic islet secretory potential against interleukin-1β (IL-1β) without affecting glutamate decarboxylase expression or nitric oxide production. FEBS Lett 337: 298-302, 1994.
30. Eizirik DL, Delaney CA, Green MH, Cunningham JM, Thorpe JR, Pipeleers DG, Hellerstrom C, and Green IC: Nitric oxide donors decrease the function and survival of human pancreatic islets. Mol Cell Endocrinol 118: 71-83, 1996.
31. Welsh N, and Sandler S: Interleukin-1β induces nitric oxide production and inhibits the activity of aconitase without decreasing glucose oxidation rates in isolated mouse pancreatic islets. Biochem Biophys Res Commun 182: 333-340, 1992.
32. Cetkovic-Cvrlje M, and Eizirik DL: TNF-α and IFN-γ potentiate the deleterious effects of IL-1β on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine 6: 399-406, 1994.
33. Eizirik DL, Welsh M, Strandell E, Welsh N, and Sandier S: Interleukin-1β depletes insulin messenger ribonucleic acid and increases the heat shock protein hsp70 in mouse pancreatic islets without imparing the glucose metabolism. Endocrinology 127: 2290-2297, 1990.
34. Eizirik DL: Interleukin-1β induces an early decrease in insulin release, (pro)insulin biosynthesis and insulin mRNA in mouse pancreatic islets by a mechanism dependent on gene transcription and protein synthesis. Autoimmunity 10: 107-114, 1991.
35. Eizirik DL, Sandier S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, and Hellerstrom C: Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 93: 1968-1974, 1994.
36. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerstrom C, and Andersson A: Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury. Proc Natl Acad Sci USA 91: 9253-9256, 1994.
37. Delaney CA, Green MH, Lowe JE, and Green IC: Endogenous nitric oxide induced by interleukin-1β in rat islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the "comet" assay. FEBS Lett 333: 291-295, 1993.
38. Fehsel K, Jalowy A, Qi S, Burkart V, Hartmann B, and Kolb H: Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes 42: 496-500, 1993.
39. Tamir S, Burney S, and Tannenbaum SR: DNA damage by nitric oxide. Chem Res Toxicol 9: 821-827, 1996.
40. Delaney CA, and Eizirik DL: Intracellular targets for nitric oxide toxicity to pancreatic β-cells. Brazilian J Med Biol Res 29: 569-579, 1996.
41. Wilson GL, Patton N, LeDoux SP: Mitochondrial DNA in β-cells is a sensitive target for damage by nitric oxide. Diabetes 46: 1291-1295, 1997.
42. Radons J, Heller B, Burkle A, Hartmann B, Rodriguez ML, Kroncke KD, Burkart V, and Kolb H: Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion. Biochem Biophys Res Commun 199: 1270-1277, 1994.
43. Heller B, Wang ZQ, Wagner EF, Radons J, Burkle A, Fehsel K, Burkart V, and Kolb H: Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J Biol Chem 270: 11176-11180, 1995.
44. Eizirik DL, Sandler S, Welsh N, Bendtzen K, and Hellerstrom C: Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. Autoimmunity 19: 193-198, 1994.
45. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Schulz R, Lakey JR, Warnock GL, and Rajotte RV: Human pancreatic islet β-cell destruction by cytokines is independent of nitric oxide production. J Clin Endocrinol Metab 79: 1058-1062, 1994.
46. Wilson GL, Patton NJ, McCord JM, Mullins DW, and Mossman BT: Mechanisms of streptozotocin- and alloxan-induced damage in rat B cells. Diabetologia 27: 587-591, 1984.
47. Cetkovic-Cvrlje M, Sandier S, and Eizirik DL: Nicotinamide and dexamethasone inhibit interleukin-1-induced nitric oxide production by RINm5F cells without decreasing messenger ribonucleic acid expression for nitric oxide synthase. Endocrinology 133: 1739-1743, 1993.
48. Delaney CA, Tyrberg B, Bouwens L, Vaghef H, Hellman B, and Eizirik DL: Sensitivity of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS Lett 394: 300-306, 1996.
49. Delaney CA, Pavlovic D, Hoorens A, Pipeleers DG, and Eizirik DL: Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 138: 2610-2614, 1997.
50. Krippeit-Drews P, Kroncke KD, Welker S, Zempel G, Roenfeldt M, Ammon HP, Lang F, and Drews G: The effects of nitric oxide on the membrane potential and ionic currents of mouse pancreatic B cells. Endocrinology 136: 5363-5369, 1995.
51. Dimmeler S, Haendeler J, Nehls M, and Zeiher AM: Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 185: 601-607, 1997.
52. Loscalzo J, and Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38: 87-104, 1995.
53. Bauer H, Jung T, Tsikas D, Stichtenoth DO, Frolich JC, and Neumann C: Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells. Immunology 90: 205-211, 1997.
54. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, and Beckman JS: Peroxynitrite, a cloaked oxidant formed by nitric oxide and Superoxide. Chem Res Toxicol 5: 834, 1992.
55. Beckman JS, and Koppenol WH: Nitric oxide, Superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 271: C1424-1437, 1996.
56. Szabo C: The pathophysiological role of peroxynitrite in shock, inflammation, and ischemiareperfusion injury. Shock 6: 79-88, 1996.
57. Kaur H, and Halliwell B: Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 350: 9-12, 1994.
58. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, and Thompson JA: Nitration and inactivation of manganese Superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93: 11853-11858, 1996.
59. Suarez-Pinzon WL, Szabo C, and Rabinovitch A: Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet β-cells. Diabetes 46: 907-911, 1997.
60. Lin KT, Xue JY, Nomen M, Spur B, and Wong PY: Peroxynitrite-induced apoptosis in HL-60 cells. J Biol Chem 270: 16487-16490, 1995.
61. Grankvist K, Marklund SL, and Taljedal IB: CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and gluathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J 199: 393-398, 1981.
62. Malaisse WJ, Malaisse-Lagae F, Sener A, and Pipeleers DG: Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci USA 79: 927-930, 1982.
63. Nunoshiba T, deRojas-Walker T, Wishnok JS, Tannenbaum SR, and Demple B: Activation by nitric oxide of an oxidative-stress response that defends Escherichia coli against activated macrophages. Proc Natl Acad Sci USA 90: 9993-9997, 1993.
64. Hausladen A, Privalle CT, Keng T, DeAngelo J, and Stamler JS: Nitrosative stress: activation of the transcription factor OxyR. Cell 86: 719-729, 1996.
65. Nunoshiba T, DeRojas-Walker T, Tannenbaum SR, and Demple B: Roles of nitric oxide in inducible resistance of Escherichia coli to activated murine macrophages. Infect Immun 63: 794-798, 1995.
66. Kwiatkowski AV, and Shapleigh JP: Requirement of nitric oxide for induction of genes whose products are involved in nitric oxide metabolism in Rhodobacter sphaeroides. J Biol Chem 271: 24382-24388, 1996.
67. Nussler AK, Geller DA, Sweetland MA, Di Silvio M, Billiar TR, Madariaga JB, Simmons RL, and Lancaster JR Jr: Induction of nitric oxide synthesis and its reactions in cultured human and rat hepatocytes stimulated with cytokines plus LPS. Biochem Biophys Res Commun 194; 826-835, 1993.
68. Corbett JA, and McDaniel ML: Reversibility of interleukin-1β-induced islet destruction and dysfunction by the inhibition of nitric oxide synthase. Biochem J 299: 719-724, 1994.
69. Welsh N, Margulis B, Borg LA, Wiklund HJ, Saldeen J, Flodström M, Mello MA, Andersson A, Pipeleers DG, Hellerstrom C, and Eizirik DL: Differences in the expression of heat-shock proteins and antigxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Mol Med 1: 806-820, 1995.
70. Welch MJ: Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72: 1063-1081, 1992.
71. Kim YM, de Vera ME, Watkins SC, and Billiar TR: Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-α-induced apoptosis by inducing heat shock protein 70 expression. J Biol Chem 272: 1402-1411, 1997.
72. de Vera ME, Wong JM, Znou JY, Tzeng E, Wong HR, Billiar TR, and Geller DA: Cytokine-induced nitric oxide synthase gene transcription is blocked by the heat shock response in human liver cells. Surgery 120: 144-149, 1996.
73. Feinstein DL, Galea E, Aquino DA, Li GC, Xu H, and Reis DJ: Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFκBactivation. J Biol Chem 271: 17724-17732, 1996.
74. Welsh M, Eizirik DL, and Strandell E: Heat-shock treatment of mouse pancreatic islets results in a partial loss of islet cells but no remaining functional impairment among the surviving β-cells. J Mol Endocrinol 1: 27-31, 1988.
75. Bellmann K, Wenz A, Radons J, Burkart V, Kleemann R, and Kolb H: Heat shock induces resistance in rat pancreatic islet cells against nitric oxide, oxygen radicals and streptozotocin toxicity in vitro. J Clin Invest 95: 2840-2845, 1995.
76. Helqvist S, Polla BS, Johannesen J, and Nerup J: Heat shock protein induction in rat pancreatic islets by recombinant human interleukin 1β. Diabetologia 34: 150-156, 1991.
77. Strandell E, Buschard K, Saldeen J, and Welsh N: Interleukin-1β induces the expression of hsp70, heme oxygenase and Mn-SOD in FACS-purified rat islet β-cells, but not in α-cells. Immunol Lett 48: 145-148, 1995.
78. Margulis BA, Sandier S, Eizirik DL, Welsh N, and Welsh M: Liposomal delivery of purified heat shock protein hsp70 into rat pancreatic islets as protection against interleukin 1β-induced impaired β-cell function. Diabetes 40: 1418-1422, 1991.
79. Bellmann K, Jaattela M, Wissing D, Burkart V, and Kolb H: Heat shock protein hsp70 overexpression confers resistance against nitric oxide. FEBS Lett 391: 185-188, 1996.
80. Bellmann K, Hui L, Radons J, Burkart V, and Kolb H: Low stress response enhances vulnerability of islet cells in diabetes-prone BB rats. Diabetes 46: 232-236, 1997.
81. Caplen NJ, Patel A, Millward A, Campbell RD, Ratanachaiyavong S, Wong FS, and Demaine AG: Complement C4 and heat shock protein 70 (hsp70) genotypes and type I diabetes mellirus. Immunogenetics 32: 427-430, 1990.
82. Pugliese A, Awdeh ZL, Galluzzo A, Yunis EJ, Alper CA, and Eisenbarth GS: No independent association between hsp70 gene polymorphism and IDDM. Diabetes 41: 788-791, 1992.
83. Kawaguchi Y, Ikegami H, Fukuda M, Fujioka Y, Shima K, and Ogihara T: Polymorphism of hsp70 gene is not associated with type 1 (insulin-dependent) diabetes mellitus in Japanese. Diabetes Res Clin Pract 21: 103-107, 1993.
84. Motterlini R, Hidalgo A, Sammut I, Shah KA, Mohammed S, Srai K, and Green CJ: A precursor of the nitric oxide donor SIN-1 modulates the stress protein heme oxygenase-1 in rat liver. Biochem Biophys Res Commun 225: 167-172, 1996.
85. Durante W, Kroll MH, Christodoulides N, Peyton KJ, and Schafer AI: Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circulation Res 80: 557-564, 1997.
86. Borg HLA, Cagliero E, Sandler S, Welsh N, and Eizirik DL: Interleukin-1β increases the activity of Superoxide dismutase in rat pancreatic islets. Endocrinology 130: 2851-2857, 1992.
87. Bigdeli N, Niemann A, Sandier S, and Eizirik DL: Dissociation between interleukin-1β-induced expression of mRNA for Superoxide dismutase and nitric oxide synthase in insulin-producing cells. Biochem Biophys Res Commun 203: 1542-1547, 1994.
88. Bedoya FJ, Flodström M, and Eizirik DL: Pyrrolidine dithiocarbamate prevents IL-1-induced nitric oxide synthase mRNA, but not Superoxide dismutase mRNA, in insulin producing cells. Biochem Biophys Res Commun 210: 816-822, 1995.
89. Meister A: On the antioxidant effects of ascorbic acid and glutathione. Biochem Pharmacol 44: 1905-1915, 1992.
90. Luperchio S, Tamir S, and Tannenbaum SR: NO-induced oxidative stress and glutathione metabolism in rodent and human cells. Free Rad Biol Med 21: 513-519, 1996.
91. Kromer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3: 614-620, 1997.
92. Iwahashi H, Hanafusa T, Eguchi Y, Nakajima H, Miyagawa J, Itoh N, Tomita K, Namba M, Kuwajima M, Noguchi T, Tsujimoto Y, and Matsuzawa Y: Cytokine-induced apoptotic cell death in a mouse pancreatic beta-cell line: inhibition by Bcl-2. Diabetologia 39: 530-536, 1996.
93. Liu Y, Rabinovitch A, Suarez-Pinzon W, Muhkerjee B, Brownlee M, Edelstein D, and Federoff HJ: Expression of the bcl-2 gene from a defective HSV-I amplicon vector protects pancreatic β-cells from apoptosis. Hum Gene Ther 7: 1719-1726, 1996.
94. Eizirik DL, Cagliero E, Bjorklund A, and Welsh N: Interleukin-1β induces the expression of an isoform of nitric oxide synthase in insulin-producing cells, which is similar to that observed in activated macrophages. FEBS Lett 308: 249-252, 1992.
95. Corbett JA, Wang JL, Sweetland MA, Lancaster JR Jr, and McDaniel ML: Interleukin 1β induces the formation of nitric oxide by β-cells purified from rodent islets of Langerhans: evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 90: 2384-2391, 1992.
96. Ling Z, In't Veld PA, and Pipeleers DG: Interaction of interleukin-1 with islet β-cells: distinction between indirect, aspecific cytotoxicity and direct, specific functional suppression. Diabetes 42: 56-65, 1993.
97. Kleemann R, Rothe H, Kolb-Bachofen V, Xie QW, Nathan C, Martin S, and Kolb H: Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Lett 328: 9-12, 1993.
98. Niemann A, Bjorklund A, and Eizirik DL: Studies on the molecular regulation of the inducible form of nitric oxide synthase (iNOS) in insulin-producing cells. Mol Cell Endocrinol 106: 151-155, 1994.
99. Schuit F, In't Veld P, and Pipeleers D: Glucose stimulates proinsulin biosynthesis by a dose-dependent recruitment of pancreatic beta cells. Proc Natl Acad Sci USA 85: 3865-3869, 1988.
100. Corbett JA, and McDaniel ML: Intraislet release of interleukin-1 inhibits β-cell function by inducing β-cell expression of inducible nitric oxide synthase. J Exp Med 181: 559-568, 1995.
101. Pipeleers DG, in't Veld PA, Van de Winkel M, Maes E, Schuit FC, and Gepts W: A new in vitro model for the study of pancreatic A and B cells. Endocrinology 117: 806-816, 1985.
102. Wiegand F, Kroncke KD, and Kolb-Bachofen V: Macrophage-generated nitric oxide as cytotoxic factor in destruction of alginate-encapsulated islets: protection by arginine analogs and/or coencapsulated erythrocytes. Transplantation 56: 1206-1212, 1993.
103. Suschek C, Fehsel K, Kroncke KD, Sommer A, and Kolb-Bachofen V: Primary cultures of rat islet capillary endothelial cells: constitutive and cytokine-inducible macrophage-like nitric oxide synthases are expressed and activities regulated by glucose concentration. Am J Pathol 145: 685-695, 1994.
104. Steiner L, Kroncke KD, Fehsel K, and Kolb-Bachofen V: Endothelial cells as cytotoxic effector cells: cytokine-activated rat islet endothelial cells lyse syngeneic islet cells via nitric oxide. Diabetologia 40: 150-155, 1997.
105. Corbett JA, Sweetland MA, Wang JL, Lancaster JR Jr, and McDaniel ML: Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA 90: 1731-1735, 1993.
106. Kolb H: Mouse models of insulin dependent diabetes: low-dose streptozotocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 3: 751-778, 1987.
107. Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL, and Liew FY: Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem Biophys Res Commun 178: 913-920, 1991.
108. Kolb H, Kiesel U, Kroncke KD, and Kolb-Bachofen V: Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci 49: P1213-1217, 1991.
109. Holstad M, and Sandier S: Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 15: 311-314, 1993.
110. Rothe H, Faust A, Schade U, Kleeman R, Bosse G, Hibino T, Martin S, and Kolb H: Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-γ, but not of interleukin-4. Diabetologia 37: 1154-1158, 1994.
111. Welsh M, Welsh N, Bendtzen K, Mares J, Strandell E, Oberg C, and Sandier S: Comparison of mRNA contents of interleukin-1β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice. Diabetologia 38: 153-160, 1995.
112. Rabinovitch A, Suarez-Pinzon W, El Sheikh A, Sorensen O, and Power RF: Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlates with β-cell destructive insulitis and IDDM. Diabetes 45: 749-754, 1996.
113. Jiang Z, and Woda BA: Cytokine gene expression in the islets of the diabetic Biobreeding/Worcester rat. J Immunol 146: 2990-2994, 1991.
114. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, and Bleackley R: Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS-expressing cells and relationships to cytokines expressed in the islets. Endocrinology 137: 2093-2099, 1996.
115. Reddy S, Kaill S, Poole CA, and Ross J: Inducible nitric oxide synthase in pancreatic islets of the non-obese diabetic mouse: a light and confocal microscopical study of its ontogeny, co-localization and up-regulation following cytokine administration. Histochem J 29: 53-64, 1997.
116. Hirasawa K, Jun HS, Maeda K, Kawaguchi Y, Itagaki S, Mikami T, Baek HS, Doi K, and Yoon JW: Possible role of macrophage-derived soluble mediators in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice. J Virol 71: 4024-4031, 1997.
117. Corbett JA, Mikhael A, Shimizu J, Frederick K, Misko TP, McDaniel ML, Kanagawa O, and Unanue ER: Nitric oxide production in islets from nonobese diabetic mice: aminoguanidinesensitive and -resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 90: 8992-8995, 1993.
118. Bowman MA, Simell OG, Peck AB, Cornelius J, Luchetta R, Look Z, MacLaren NK, and Atkinson MA: Pharrnacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice. J Pharmacol Exp Ther 279: 790-794, 1996.
119. Wu G: Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44: 360-364, 1995.
120. Lindsay RM, Smith W, Rossiter SP, McIntyre MA, Williams BC, and Baird JD: N-Nitro-l-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes 44: 365-368, 1995.